StabiliT ERX bone cement, which has five times greater viscosity than other Polymethylmethacrylate (PMMA) bone cements and about two times the viscosity of Dfine’s StabiliT ER2 cement, is designed for use with the company’s vertebral augmentation system for treating complex osteoporotic and oncologic fractures with large voids.

The company said StabiliT vertebral augmentation system harnesses the power of radiofrequency-targeted vertebral augmentation (RF-TVA) process, which places a small tube into the fractured vertebra to create a cavity.

In addition to higher viscosity, StabiliT ERX bone cement provides extended working time allowing physicians with procedural flexibility and offers greater radiopacity during cement delivery for improving visibility under fluoroscopy.

Radiology Imaging Associates interventional radiologist Nick Yee said patients with complex fractures such as non-healed vertebra plana are difficult to treat as these fractures have a limited amount of bone to work and stabilize the vertebra.

"With its significantly higher viscosity, StabiliT ERX affords a more targeted and controlled delivery – potentially reducing the likelihood of extravasation while still allowing for easy delivery into the vertebral body," Yee added.